Azimilide (BioDeep_00000176382)

   

human metabolite blood metabolite


代谢物信息卡片


2,4-Imidazolidinedione, 1-(((5-(4-chlorophenyl)-2-furanyl)methylene)amino)-3-(4-(4-methyl-1-piperazinyl)butyl)-, dihydrochloride

化学式: C23H28ClN5O3 (457.1881)
中文名称: 阿齐利特
谱图信息: 最多检出来源 Homo sapiens(blood) 100%

分子结构信息

SMILES: CN1CCN(CC1)CCCCN2C(=O)CN(C2=O)N=CC3=CC=C(O3)C4=CC=C(C=C4)Cl
InChI: InChI=1S/C23H28ClN5O3/c1-26-12-14-27(15-13-26)10-2-3-11-28-22(30)17-29(23(28)31)25-16-20-8-9-21(32-20)18-4-6-19(24)7-5-18/h4-9,16H,2-3,10-15,17H2,1H3

描述信息

C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent
D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers
D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
D000077264 - Calcium-Regulating Hormones and Agents
D049990 - Membrane Transport Modulators
C93038 - Cation Channel Blocker

同义名列表

7 个代谢物同义名

2,4-Imidazolidinedione, 1-(((5-(4-chlorophenyl)-2-furanyl)methylene)amino)-3-(4-(4-methyl-1-piperazinyl)butyl)-, dihydrochloride; 1-(((5-(4-Chlorophenyl)-2-furanyl)methylene)amino)-3-(4-(4-methyl-1-piperazinyl)butyl)-2,4-imidazolidinedione dihydrochloride; 1-({[5-(4-chlorophenyl)furan-2-yl]methylidene}amino)-3-[4-(4-methylpiperazin-1-yl)butyl]imidazolidine-2,4-dione; Azimilide dihydrochloride; AZIMILIDE; Azmilide; Azimilide



数据库引用编号

11 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 8 AXIN2, CASQ2, CYP2C9, CYP3A4, FKBP1B, KCNQ1, NOX4, PRKAA2
Endoplasmic reticulum membrane 5 CYP1A2, CYP2C9, CYP3A4, HSP90B1, NOX4
Nucleus 4 AXIN2, HSP90B1, NOX4, PRKAA2
cytosol 4 AXIN2, HSP90B1, KCNN4, PRKAA2
dendrite 1 PRKAA2
centrosome 1 AXIN2
nucleoplasm 3 PRKAA2, SCN5A, SCNN1G
Cell membrane 7 GJA5, KCNE1, KCNH2, KCNN4, KCNQ1, NOX4, SCN5A
ruffle membrane 1 KCNN4
Multi-pass membrane protein 9 CACNA1I, GJA5, KCNA3, KCNH2, KCNN4, KCNQ1, NOX4, SCN5A, SCNN1G
cell junction 1 SCN5A
cell surface 3 KCNE1, KCNH2, SCN5A
glutamatergic synapse 1 KCNA3
Golgi apparatus 1 PRKAA2
neuronal cell body 3 KCNN4, KCNQ1, PRKAA2
presynaptic membrane 1 KCNA3
sarcolemma 1 SCN5A
smooth endoplasmic reticulum 1 HSP90B1
Lysosome 2 KCNE1, KCNQ1
plasma membrane 12 AXIN2, CACNA1I, CYP2C9, GJA5, KCNA3, KCNE1, KCNH2, KCNN4, KCNQ1, NOX4, SCN5A, SCNN1G
Membrane 11 CACNA1I, CYP3A4, FKBP1B, HSP90B1, KCNA3, KCNH2, KCNN4, KCNQ1, NOX4, PRKAA2, SCN5A
apical plasma membrane 3 KCNE1, KCNQ1, SCNN1G
axon 2 KCNA3, PRKAA2
basolateral plasma membrane 1 KCNQ1
caveola 1 SCN5A
extracellular exosome 3 HSP90B1, SCNN1G, SOD2
endoplasmic reticulum 4 HSP90B1, KCNQ1, NOX4, SCN5A
perinuclear region of cytoplasm 5 HSP90B1, KCNA3, KCNH2, NOX4, SCN5A
gap junction 1 GJA5
intercalated disc 2 GJA5, SCN5A
mitochondrion 2 NOX4, SOD2
protein-containing complex 1 HSP90B1
intracellular membrane-bounded organelle 3 CYP1A2, CYP2C9, CYP3A4
Microsome membrane 3 CYP1A2, CYP2C9, CYP3A4
Single-pass type I membrane protein 1 KCNE1
extracellular region 1 HSP90B1
Mitochondrion matrix 1 SOD2
mitochondrial matrix 1 SOD2
external side of plasma membrane 1 SCNN1G
T-tubule 1 SCN5A
Z disc 4 CASQ2, FKBP1B, KCNE1, SCN5A
beta-catenin destruction complex 1 AXIN2
nucleolus 2 NOX4, SCN5A
midbody 1 HSP90B1
Early endosome 1 KCNQ1
vesicle 1 KCNN4
postsynaptic membrane 1 KCNA3
Apical cell membrane 3 KCNE1, KCNQ1, SCNN1G
Cell projection, ruffle membrane 1 KCNN4
Cytoplasm, perinuclear region 2 NOX4, SCN5A
Membrane raft 3 KCNA3, KCNE1, KCNQ1
Cell junction, focal adhesion 1 NOX4
focal adhesion 2 HSP90B1, NOX4
mitochondrial nucleoid 1 SOD2
sarcoplasmic reticulum 2 CASQ2, FKBP1B
collagen-containing extracellular matrix 1 HSP90B1
Cell junction, gap junction 1 GJA5
connexin complex 1 GJA5
lateral plasma membrane 2 KCNQ1, SCN5A
nuclear speck 1 PRKAA2
Late endosome 1 KCNQ1
neuron projection 2 KCNN4, KCNQ1
ciliary base 1 KCNQ1
cell projection 1 GJA5
[Isoform 5]: Cytoplasm 1 NOX4
Nucleus, nucleolus 1 NOX4
Basolateral cell membrane 1 KCNQ1
[Isoform 2]: Cell membrane 1 KCNA3
monoatomic ion channel complex 2 KCNH2, KCNQ1
Cytoplasmic vesicle membrane 1 KCNQ1
sodium channel complex 1 SCNN1G
Melanosome 1 HSP90B1
cytoplasmic stress granule 1 PRKAA2
sperm plasma membrane 1 HSP90B1
[Isoform 3]: Cytoplasm 1 NOX4
Cell membrane, sarcolemma, T-tubule 1 SCN5A
inward rectifier potassium channel complex 1 KCNH2
voltage-gated potassium channel complex 5 KCNA3, KCNE1, KCNH2, KCNN4, KCNQ1
endoplasmic reticulum lumen 1 HSP90B1
voltage-gated calcium channel complex 1 CACNA1I
transport vesicle 1 KCNQ1
Sarcoplasmic reticulum membrane 2 CASQ2, FKBP1B
perinuclear endoplasmic reticulum 1 NOX4
calyx of Held 1 KCNA3
Sarcoplasmic reticulum lumen 2 CASQ2, HSP90B1
calcium channel complex 2 CASQ2, FKBP1B
junctional sarcoplasmic reticulum membrane 1 CASQ2
[Isoform 1]: Cell membrane 1 KCNA3
nucleotide-activated protein kinase complex 1 PRKAA2
voltage-gated sodium channel complex 1 SCN5A
[Isoform 4]: Nucleus 1 NOX4
endocytic vesicle lumen 1 HSP90B1
NADPH oxidase complex 1 NOX4
endoplasmic reticulum chaperone complex 1 HSP90B1
[Isoform 6]: Cytoplasm 1 NOX4
[Isoform 3]: Cytoplasm, perinuclear region 1 KCNA3
lumenal side of membrane 1 KCNQ1
basolateral part of cell 1 KCNQ1


文献列表

  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • Leif Carlsson, Denis Chartier, Stanley Nattel. Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog. Journal of cardiovascular pharmacology. 2006 Jan; 47(1):123-32. doi: 10.1097/01.fjc.0000196242.04384.c3. [PMID: 16424796]
  • P Riley, P C Figary, J R Entwisle, A L Roe, G A Thompson, R Ohashi, N Ohashi, T J Moorehead. The metabolic profile of azimilide in man: in vivo and in vitro evaluations. Journal of pharmaceutical sciences. 2005 Sep; 94(9):2084-95. doi: 10.1002/jps.20429. [PMID: 16052551]
  • Roger D Toothaker, Alfred E Corey, Suzanne N Valentine, Jeff R Agnew, Nikhil Parekh, Werner Moehrke, Gary A Thompson, James H Powell. Influence of coadministration on the pharmacokinetics of azimilide dihydrochloride and digoxin. Journal of clinical pharmacology. 2005 Jul; 45(7):773-80. doi: 10.1177/0091270005276948. [PMID: 15951467]
  • Mohamed El Mouelhi, Dan J Worley, Barbara Kuzmak, Anthony J Destefano, Gary A Thompson. Influence of ketoconazole on azimilide pharmacokinetics in healthy subjects. British journal of clinical pharmacology. 2004 Dec; 58(6):641-7. doi: 10.1111/j.1365-2125.2004.02222.x. [PMID: 15563362]
  • Alfred E Corey, Jeffrey R Agnew, Eileen C King, Nikhil J Parekh, James H Powell, Gary A Thompson. Effect of mild and moderate hepatic impairment on azimilide pharmacokinetics following single dose oral administration. Journal of pharmaceutical sciences. 2004 May; 93(5):1279-86. doi: 10.1002/jps.20060. [PMID: 15067704]
  • Mohamed El Mouelhi, Dan J Worley, Barbara Kuzmak, Anthony J Destefano, Gary A Thompson. Influence of azimilide on CYP2C19-mediated metabolism. Journal of clinical pharmacology. 2004 Apr; 44(4):373-8. doi: 10.1177/0091270004263469. [PMID: 15051744]
  • Alfred E Corey, Jeffrey R Agnew, Suzanne N Valentine, Nikhil J Parekh, James H Powell, Gary A Thompson. Effect of severe renal impairment on the pharmacokinetics of azimilide following single dose oral administration. British journal of clinical pharmacology. 2002 Nov; 54(5):449-52. doi: 10.1046/j.1365-2125.2002.01664.x. [PMID: 12445022]
  • R R Brooks, S F Pong, N J Izzo, T J Moorehead, M Gopalakrishnan, D J Triggle. Interaction of azimilide with neurohumoral and channel receptors. Biochemical pharmacology. 2001 Oct; 62(7):883-92. doi: 10.1016/s0006-2952(01)00737-7. [PMID: 11543723]
  • L Phillips, T H Grasela, J R Agnew, E A Ludwig, G A Thompson. A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide. Clinical pharmacology and therapeutics. 2001 Oct; 70(4):370-83. doi: . [PMID: 11673753]
  • A E Corey, J R Agnew, S N Valentine, J D Nesbitt, D L Wagner, J H Powell, G A Thompson. Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation. Journal of clinical pharmacology. 1999 Dec; 39(12):1272-6. doi: 10.1177/00912709922012088. [PMID: 10586393]
  • A Corey, J Agnew, J Brum, N Parekh, S Valentine, M Williams. Pharmacokinetics and pharmacodynamics following intravenous doses of azimilide dihydrochloride. Journal of clinical pharmacology. 1999 Dec; 39(12):1263-71. doi: 10.1177/00912709922012079. [PMID: 10586392]
  • X Q Qi, D Newman, P Dorian. Azimilide decreases defibrillation voltage requirements and increases spatial organization during ventricular fibrillation. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing. 1999 Mar; 3(1):61-7. doi: 10.1023/a:1009879708404. [PMID: 10354978]
  • A Corey, J Agnew, J Bao, P Bryson, P Comer, S Griffith, J Li. Effect of age and gender on azimilide pharmacokinetics after a single oral dose of azimilide dihydrochloride. Journal of clinical pharmacology. 1997 Oct; 37(10):946-53. doi: 10.1002/j.1552-4604.1997.tb04269.x. [PMID: 9505986]
  • T Herzer, C A Wagner, S Waldegger, F Lang, A E Busch. Effect of channel modulation and pH on IsK inhibition by the novel class III antiarrhythmic azimilide (NE-10064). European journal of pharmacology. 1995 Oct; 291(2):205-8. doi: 10.1016/0922-4106(95)90144-2. [PMID: 8566172]